News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nomir Medical’s Noveon(R) Device Achieves 76 Percent Response Rate in Pivotal Trial for the Treatment of Onychomycosis


3/5/2009 10:08:25 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced today positive preliminary data from the pivotal product registration trial evaluating the Company’s advanced Noveon® direct optical energy device for the treatment of onychomycosis (toenail fungus). The Noveon is a light-based system that photo-biologically targets the elimination of bacterial and fungal infections through a unique, near-infrared, photo-inactivation effect, while preserving healthy tissue and promoting recovery.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES